Vanna Chiaron Sileni

19PUBLICATIONS
126CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyPredictive and prognostic markersMolecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Aug 04, 2026
Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.

|Aug 05, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.

Jeffrey Weber, Michele Del Vecchio, Mario Mandalá

|Mar 07, 2024
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.

Jason J Luke, Paolo A Ascierto, Muhammad A Khattak

|Jan 03, 2024
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.

Paolo A Ascierto, Milena Casula, Jenny Bulgarelli

|Aug 12, 2023
Molecular Modeling Unveils the Effective Interaction of B-RAF Inhibitors with Rare B-RAF Insertion Variants.

Maria Chiara Scaini, Luisa Piccin, Davide Bassani

|Jul 28, 2023
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial.

Paolo A Ascierto, Reinhard Dummer, Helen J Gogas

Pageof 4

Frequent Collaborators

11 joint publications

Paolo Antonio Ascierto

6 joint publications

Helen J Gogas

6 joint publications

Reinhard Dummer

5 joint publications

Mario Mandalà